SCA
Summit Creek Advisors’s Ligand Pharmaceuticals LGND Stock Holding History
| Quarter | Market Value | Status | Shares |
Shares Change % | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2021
Q1 | – | Sell |
-74,822
| Closed | -$7.44M | – | 68 |
|
|
2020
Q4 | $7.44M | Sell |
74,822
-4,160
| -5% | -$414K | 0.95% | 48 |
|
|
2020
Q3 | $7.53M | Sell |
78,982
-7,440
| -9% | -$709K | 1.12% | 42 |
|
|
2020
Q2 | $9.67M | Buy |
86,422
+15,840
| +22% | +$1.77M | 1.42% | 35 |
|
|
2020
Q1 | $5.13M | Sell |
70,582
-380
| -0.5% | -$27.6K | 1.03% | 42 |
|
|
2019
Q4 | $7.4M | Sell |
70,962
-400
| -0.6% | -$41.7K | 1.16% | 45 |
|
|
2019
Q3 | $7.1M | Buy |
71,362
+2,620
| +4% | +$261K | 1.19% | 38 |
|
|
2019
Q2 | $7.85M | Buy |
68,742
+21,170
| +45% | +$2.42M | 1.32% | 37 |
|
|
2019
Q1 | $5.98M | Sell |
47,572
-80
| -0.2% | -$10.1K | 1.07% | 43 |
|
|
2018
Q4 | $6.47M | Buy |
47,652
+19,555
| +70% | +$2.65M | 1.31% | 42 |
|
|
2018
Q3 | $7.71M | Sell |
28,097
-22,290
| -44% | -$6.12M | 1.24% | 42 |
|
|
2018
Q2 | $10.4M | Sell |
50,387
-4,700
| -9% | -$974K | 1.87% | 25 |
|
|
2018
Q1 | $9.1M | Buy |
55,087
+12,510
| +29% | +$2.07M | 1.65% | 31 |
|
|
2017
Q4 | $5.83M | Sell |
42,577
-315
| -0.7% | -$43.1K | 1.09% | 46 |
|
|
2017
Q3 | $5.84M | Sell |
42,892
-325
| -0.8% | -$44.3K | 1.15% | 42 |
|
|
2017
Q2 | $5.25M | Sell |
43,217
-3,555
| -8% | -$432K | 1.08% | 46 |
|
|
2017
Q1 | $4.95M | Sell |
46,772
-14,875
| -24% | -$1.57M | 1.04% | 44 |
|
|
2016
Q4 | $6.26M | Sell |
61,647
-87,775
| -59% | -$8.92M | 1.07% | 42 |
|
|
2016
Q3 | $15.3M | Buy |
149,422
+31,150
| +26% | +$3.18M | 2.5% | 15 |
|
|
2016
Q2 | $14.1M | Sell |
118,272
-7,925
| -6% | -$945K | 2.4% | 18 |
|
|
2016
Q1 | $13.5M | Buy |
126,197
+46,162
| +58% | +$4.94M | 2.13% | 25 |
|
|
2015
Q4 | $8.68M | Buy |
80,035
+9,403
| +13% | +$1.02M | 1.45% | 36 |
|
|
2015
Q3 | $6.05M | Buy |
+70,632
| New | +$6.05M | 0.98% | 45 |
|